3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
10
Phase 3
2
Phase 1/2
2
Phase 1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Carcinoma, Non-Small-Cell Lung
146
Breast Neoplasms
112
Prostatic Neoplasms
59
Multiple Myeloma
55
Neoplasms
54
Lung Neoplasms
49
Neoplasm Metastasis
42
Colorectal Neoplasms
34
Ovarian Neoplasms
33
Parkinson Disease 4, Autosomal Dominant Lewy Body
31
Leukemia, Lymphocytic, Chronic, B-Cell
31
Recurrence
26
Leukemia, Myeloid, Acute
26
Carcinoma, Renal Cell
25
Urinary Bladder Neoplasms
24
Triple Negative Breast Neoplasms
21
Small Cell Lung Carcinoma
21
Myasthenia Gravis
21
Endometrial Neoplasms
21
Carcinoma, Hepatocellular
21
Squamous Cell Carcinoma of Head and Neck
20
Lymphoma, Large B-Cell, Diffuse
20
Melanoma
18
Lymphoma, Follicular
18
Nasopharyngeal Carcinoma
17
Fallopian Tube Neoplasms
16
Pancreatic Neoplasms
15
Non-Muscle Invasive Bladder Neoplasms
15
Brain Neoplasms
15
Stomach Neoplasms
14
Interventions
acalabrutinib
1
Vincristine
1
Rituximab
1
Prednisone
1
Doxorubicin
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoproliferative Disorders
×
90 days
×
Clear all
NCT03394365
2026-05-22
ALLELE
Pierre Fabre Medicament
Phase 3
Recruiting
115 enrolled
NCT04529772
2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3
Active not recruiting
611 enrolled